Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher T Harbison

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Personalized Medicine|May 23, 2018
The cetuximab experience: developing predictive biomarkers in oncologyChristopher T Harbison, Christine E Horak, Shirin Khambata-Ford
Molecular Systems Biology|January 17, 2007
Reconstructing dynamic regulatory mapsJason Ernst, Oded Vainas, Christopher T Harbison, et al.
Cell|May 7, 2003
Program-specific distribution of a transcription factor dependent on partner transcription factor and MAPK signalingJulia Zeitlinger, Itamar Simon, Christopher T Harbison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancerShirin Khambata-Ford, Christopher T Harbison, Lowell L Hart, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 30, 2010
Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humansLisa J Christopher, Haizheng Hong, Blisse J Vakkalagadda, et al.
Cell|August 27, 2005
Genome-wide map of nucleosome acetylation and methylation in yeastDmitry K Pokholok, Christopher T Harbison, Stuart Levine, et al.
Neuro-Oncology|November 7, 2017
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143Antonio Omuro, Gordana Vlahovic, Michael Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2018
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric CancerYelena Y Janjigian, Johanna Bendell, Emiliano Calvo, et al.
Archives of Pathology & Laboratory Medicine|October 4, 2012
Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trialChristopher T Harbison, Christine E Horak, Jean-Marie Ledeine, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2013
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumoursJean-Charles Soria, José Baselga, Nasser Hanna, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Personalized Medicine|May 23, 2018
The cetuximab experience: developing predictive biomarkers in oncologyChristopher T Harbison, Christine E Horak, Shirin Khambata-Ford
Molecular Systems Biology|January 17, 2007
Reconstructing dynamic regulatory mapsJason Ernst, Oded Vainas, Christopher T Harbison, et al.
Cell|May 7, 2003
Program-specific distribution of a transcription factor dependent on partner transcription factor and MAPK signalingJulia Zeitlinger, Itamar Simon, Christopher T Harbison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancerShirin Khambata-Ford, Christopher T Harbison, Lowell L Hart, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 30, 2010
Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humansLisa J Christopher, Haizheng Hong, Blisse J Vakkalagadda, et al.
Cell|August 27, 2005
Genome-wide map of nucleosome acetylation and methylation in yeastDmitry K Pokholok, Christopher T Harbison, Stuart Levine, et al.
Neuro-Oncology|November 7, 2017
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143Antonio Omuro, Gordana Vlahovic, Michael Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2018
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric CancerYelena Y Janjigian, Johanna Bendell, Emiliano Calvo, et al.
Archives of Pathology & Laboratory Medicine|October 4, 2012
Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trialChristopher T Harbison, Christine E Horak, Jean-Marie Ledeine, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2013
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumoursJean-Charles Soria, José Baselga, Nasser Hanna, et al.
Pageof 3